One region. Very different markets.

Our market focus spans South and Southeast Asia, alongside major pharmaceutical markets including Japan and South Korea. 

Across the region, regulation, reimbursement, healthcare infrastructure and patient access differ significantly. The right route to market depends on the product, patient population and local environment.

Our markets

One region. Very different markets.

North Asia · Japan, South Korea

Highly developed pharmaceutical markets with structured regulatory, reimbursement and specialist healthcare systems

Southeast Asia · Singapore, Malaysia, Thailand, Vietnam, Philippines, Indonesia

Diverse healthcare systems with a mix of named-patient, private-pay, tender and reimbursed routes to market

South Asia · India, Pakistan

Large patient populations with specialist care concentrated in major centres and significant variation in affordability and access

Different markets require different models

Expertise tailor made to your needs

Patient Access

The route to treatment varies by market, from named-patient access and private-pay pathways to registration and reimbursed commercialisation

Healthcare Systems

Specialist treatment may be concentrated in a small number of centres in one country and distributed across a broader hospital network in another

Commercial Approach

Some opportunities justify full registration and launch, while others are better served through focused access programmes or targeted commercial models

Scale and patient need

Vast populations. Urgent need.

~2.5B

People across the markets shown

~4.1M

New cancer cases annually across these markets, approximately one in five worldwide 

Sources: UN World Population Prospects 2024; IARC GLOBOCAN 2024

We prioritise markets where patient need, access feasibility and a sustainable commercial opportunity come together.

Let’s talk

Ready to explore the opportunity?

Whether you are considering managed access, registration or a broader regional commercial partnership, we’d welcome a conversation